Biotech Values

[DewDiligence]

ABT inks deal to_sell biosimilars in emerging markets:

https://www.prnewswire.com/news-releases/abbott-broadens-access-to-cutting-edge-biosimilars-in-key-emerging-markets-301932956.html

In emerging markets, consumers care greatly about the reputation of the manufacturer, which is why so-called “branded generics” can be a high-margin business for a company such as ABT. Biosimilars are a natural fit for ABT’s existing business in off-patent small-molecule drugs, which comprises 13% of ABT’s overall corporate sales (#msg-172393746).